

Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

1-61. (Cancelled)

62. (New) A method for treating Tumor Necrosis Factor-alpha (TNF α) mediated immune reaction that causes corneal transplant rejection in a patient, comprising topically administering to said patient an effective amount of anti-TNF α F(ab')₂ neutralizing antibody fragments.

63. (New) The method of claim 62, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are polyclonal.

64. (New) The method of claim 63, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are free of albumin, whole antibodies, pyrogens, and/or viruses.

65. (New) The method of claim 62, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are administered in combination with a dermatologically or ophthalmically acceptable carrier.